Semaglutide linked to better mental health, but careful, this isn’t randomized
STUDY: Taipale H et al, Lancet Psychiatry 2026;13:327–335, PMID: 41862258
STUDY TYPE: National cohort study (within-individual design)
EVIDENCE GRADE: Low (4/10)
FUNDING: Sigrid Jusélius Foundation, Jane and Aatos Erkko Foundation, Finnish Ministry of Social Affairs and Health
Background
GLP-1 receptor agonists (semaglutide/Ozempic, liraglutide, and others) are approved for type 2 diabetes and obesity. They also affect the brain, and we are still figuring out how they help and whether they might also harm mental health. Earlier, there was a warning about suicidality on them, but the FDA removed that on January 16, 2026 after reassuring data came out. This study adds more reassurance.
The Study
This Swedish national register study followed 95,490 adults with a diagnosis of depression or anxiety who were also using antidiabetic medications, from 2009 to 2022. It used a within-individual design — comparing each person’s periods on a GLP-1 agonist against their own periods off it — which eliminates confounding from stable individual characteristics like baseline illness severity.
The primary outcome was a composite of psychiatric hospitalization, psychiatric sick leave exceeding 14 days, self-harm hospitalization, or suicide.
Semaglutide was associated with a 42% lower risk of worsening mental illness compared to non-use periods in the same individuals (adjusted hazard ratio [aHR] 0.58). For liraglutide, the psychiatric benefits were modest but still significant (18% reduction, aHR 0.82). Exenatide and dulaglutide showed no benefit.
For secondary outcomes, semaglutide (Wegovy, Zepbound) reduced the risk of worsening depression (aHR 0.56), worsening anxiety (aHR 0.62), and worsening substance use disorder (aHR 0.53). Liraglutide reduced depression risk only (aHR 0.74). GLP-1 agonists as a group were associated with lower rates of self-harm (aHR 0.56) (it also has the weakest effect on weight). When semaglutide was compared directly against other second-line antidiabetics — including empagliflozin, dapagliflozin, and sitagliptin — it still came out ahead.
Limitations: this is observational data, causality can’t be established. Weight change and BMI weren’t captured in the registers, so we don’t know if that explains the benefits. Statistical power was limited for exenatide and dulaglutide.
Practice Implications
- GLP-1’s may worsen mental health in rare cases, but more often they prevent mental illness.
- This doesn’t mean they treat psychiatric disorders. So far, controlled trials on that are disappointing, with failures in dementia and depression and mixed results in alcohol, while epidemiologic studies are encouraging. Why? Perhaps they mainly help mental health when treating other problems like diabetes or obesity.
—Chris Aiken, MD
Director, Psych Partners
Editor in Chief, Carlat Psychiatry Report
What’s Your Take? Share in Comments
- Are you seeing mental benefits with GLP-1 agonists?
